<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02056366</url>
  </required_header>
  <id_info>
    <org_study_id>ALA_IIT01</org_study_id>
    <nct_id>NCT02056366</nct_id>
  </id_info>
  <brief_title>The Effect of α-lipoic Acid Treatment in Patient With Cardiac Autonomic Neuropathy</brief_title>
  <acronym>CANON</acronym>
  <official_title>The Effect of α-lipoic Acid Treatment in Patient With Cardiac Autonomic Neuropathy by Comparing the Change of HRV Index &amp; ANS Function:A 6month Multicenter, Randomized, Open Label Clinical Trial CANON Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Catholic University of Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if it is safe and effective to give alpha lipoic acid in
      people with cardiac autonomic neuropathy(CAN). Cardiac autonomic neuropathy(CAN) affects the
      nerves that control heart rate and blood flow to the heart in people with diabetes. CAN may
      cause problems with the rhythm of the heartbeat or decrease blood flow to the heart.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study type : Interventional Study Design : Allocation: Randomized Control: no treatment
      Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment
      Masking: Open Label Primary Purpose: Treatment Primary Outcome Measures : Heart rate
      variability(HRV) Index

      Secondary Outcome Measures : Autonomic Nerve System(ANS) function 5 test, EuroQoL 5-Dimension
      Questionnaire(EQ-5D)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Efficacy of α-lipoic Acid in patients with cardiac autonomic neuropathy</measure>
    <time_frame>up to 24weeks</time_frame>
    <description>check the Heart rate variability(HRV) Index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy of α-lipoic Acid in patients with cardiac autonomic neuropathy</measure>
    <time_frame>up to 24weeks</time_frame>
    <description>Check the Autonomic Nerve System(ANS) function 5 test</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Patients with Adverse events as a Measure of Safety</measure>
    <time_frame>up to 24weeks</time_frame>
    <description>Check the Number of Adverse events</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Cardiac Autonomic Neuropathy</condition>
  <arm_group>
    <arm_group_label>α-lipoic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>α-lipoic acid PO medication, 600mg per day, for 6weeks α-lipoic acid PO medication, 1200mg per day, for 6weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No Intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>α-lipoic acid</intervention_name>
    <description>α-lipoic acid 600mg PO medication,Per day, For 6weeks α-lipoic acid 1200mg PO medication,Per day, For 6weeks</description>
    <arm_group_label>α-lipoic acid</arm_group_label>
    <other_name>Neuropaid OD Tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Established Cardiac Autonomic Neuropathy in type 2 diabetes.

          -  aged 20 years to 80 years

          -  Capable of giving informed consent

        Exclusion Criteria :

          -  History of other significant disease such as the nerve system (Parkinson's disease,
             epilepsy, multiple sclerosis), hepatic disease, hypothyroid, etc Other medical
             condition or treatment likely to affect the autonomic nerve system

          -  HbA1C &gt; 11%

          -  Not controlled hypertension (SBP≥160mmHg, DBP≥100mmHg)

          -  Diagnosed ketoacidosis within 4 weeks

          -  Unstable cardiac disease (unstable angina or myocardial infarction )

          -  Pregnancy

          -  Involvement in other clinical trial in last 4 weeks

          -  Known or suspected sensitivity to trial products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bong Yun Cha, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Catholic University of Korea</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eulji General Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sejong General Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2014</study_first_submitted>
  <study_first_submitted_qc>February 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2014</study_first_posted>
  <last_update_submitted>February 4, 2014</last_update_submitted>
  <last_update_submitted_qc>February 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Catholic University of Korea</investigator_affiliation>
    <investigator_full_name>Chong Hwa Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Cardiac Autonomic Neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thioctic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

